Literature DB >> 19119713

Therapeutic alternatives for chronic urticaria: additional reports on omalizumab.

Sheldon L Spector, Ricardo A Tan.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19119713     DOI： 10.1016/S1081-1206(10)60232-3

Source DB:  PubMed          Journal:  Ann Allergy Asthma Immunol        ISSN： 1081-1206            Impact factor:   6.347


× No keyword cloud information.
  3 in total

1.  Omalizumab for difficult-to-treat dermatological conditions: clinical and immunological features from a retrospective real-life experience.

Authors:  Ciro Romano; Ausilia Sellitto; Umberto De Fanis; Antonella Balestrieri; Alfonso Savoia; Salvatore Abbadessa; Corrado Astarita; Giacomo Lucivero
Journal:  Clin Drug Investig       Date:  2015-03       Impact factor: 2.859

2.  [Therapeutic alternatives for antihistamine-refractory urticaria].

Authors:  M Maurer; S Altrichter; E Ardelean; K Krause; M Magerl; M Metz; F Siebenhaar; K Weller; T Zuberbier
Journal:  Hautarzt       Date:  2010-09       Impact factor: 0.751

Review 3.  Monoclonal antibodies and other biologic agents in the treatment of asthma.

Authors:  Aidan A Long
Journal:  MAbs       Date:  2009-05-04       Impact factor: 5.857
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.